Tildrakizumab is a monoclonal antibody of the IgG1 class that specifically targets the p19 subunit of IL-23, a cytokine involved in the inflammatory responses of the immune system and implicated in conditions like psoriasis and psoriatic arthritis (Figure 2) (89, 90). The gene discussed is IL23A; the disease is psoriasis.